FRANKFURT (dpa-AFX) - Eckert & Ziegler shares took the lead in the SDax on Tuesday. After a weak start, they turned positive at midday following an announcement of positive feedback from the US health authority FDA. They recently rose by 4.1 percent and reached a high since mid-June. They also made it back above the 21-day line, which many chart-oriented investors see as a positive short-term signal.

At lunchtime, Eckert & Ziegler announced that its subsidiary Pentixapharm had received positive feedback from the US Food and Drug Administration (FDA) regarding the start of a third study phase with Pentixafor, a radiopharmaceutical diagnostic agent for primary aldosteronism. This is a disease of the adrenal gland. It was also reported that this does not constitute formal approval of the development plan by the FDA. However, a protocol indicates that the clinical data was sufficient to relieve the company of the need for a Phase II trial./tih/jha/